
1. mol ther methods clin dev. 2015 may 13;2:15017. doi: 10.1038/mtm.2015.17.
ecollection 2015.

development replication-competent lentivirus assay dendritic
cell-targeting lentiviral vectors.

farley dc(1), mccloskey l(1), thorne ba(2), tareen su(2), nicolai cj(2), campbell
dj(2), bannister r(1), stewart hj(1), pearson lj(1), moyer bj(2), robbins sh(2), 
zielinski l(2), kim t(2), radcliffe pa(1), mitrophanous ka(1), gombotz wr(2),
miskin je(1), kelley-clarke b(2).

author information: 
(1)oxford biomedica (uk) limited, windrush court, transport way , oxford, uk.
(2)immune design , seattle, washington, usa.

it current regulatory requirement demonstrate absence detectable
replication-competent lentivirus (rcl) lentiviral vector products prior use
in clinical trials. immune design previously described hiv-1-based
integration-deficient lentiviral vector use cancer immunotherapy (vp02).
vp02 enveloped e1001, modified sindbis virus glycoprotein targets
dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin
(dc-sign) expressed dendritic cells vivo. vector enveloped e1001 
not transduce t-cell lines used standard hiv-1-based rcl assays, making
current rcl testing formats unsuitable testing vp02. therefore developed a
novel assay test rcl clinical lots vp02. assay, utilizes 
a murine leukemia positive control virus 293f cell line expressing the
e1001 receptor dc-sign, meets series evaluation criteria defined in
collaboration us regulatory authorities demonstrates ability 
assay format amplify detect hypothetical rcl derived vp02 vector
components. assay qualified used test six independent gmp
production lots vp02, rcl detected. propose the
evaluation criteria used rationally design novel method be
considered developing rcl assay lentiviral vector.

doi: 10.1038/mtm.2015.17 
pmcid: pmc4445008
pmid: 26029728 

